Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-11-18

FDA Approved: RYLAZE — Supplemental Application (Jazz Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved Jazz Pharmaceuticals' supplemental application for RYLAZE (ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN). The approval updates the labe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RYLAZE (ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN)

Snippet

SUPPL AP for RYLAZE (ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN)